BioPharma Resources

Drug Trial Radar · NCT07492641

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,056 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,056

Planned (sponsor's estimate)

Start

May 22, 2026

Primary completion

Apr 2029

Study completion Aug 7, 2037

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Mar 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.

Conditions

  • HR+/HER2- Breast Cancer

Interventions

  • BGB-43395Drug

    Administered orally.

  • LetrozoleDrug

    Administered orally.

  • AbemaciclibDrug

    Administered orally.

  • PalbociclibDrug

    Administered orally.

  • RibociclibDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)Time frame: Up to approximately 4 years

Locations

241 sites in 16 countries. Site status is shown where the registry gives one.

  • Alabama Oncology Princeton

    Birmingham, Alabama · Recruiting

  • Alaska Oncology and Hematology, Llc

    Anchorage, Alaska · Recruiting

  • Fairbanks Cancer Care Physicians Pc

    Fairbanks, Alaska · Recruiting

  • Pioneer Research Center

    Bullhead City, Arizona · Recruiting

  • Ironwood Cancer and Research Centers Chandler Ii

    Chandler, Arizona · Recruiting

  • City of Hope Phoenix Cancer Center

    Goodyear, Arizona · Recruiting

  • Genesis Cancer and Blood Institute Hot Springs (Harmony Park)

    Hot Springs, Arkansas · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Helios Clinical Research the Oncology Institute Fountain Valley

    Fountain Valley, California · Recruiting

  • California Research Institute

    Los Angeles, California · Recruiting

  • Ventura County Hematology Oncology Specialists

    Oxnard, California · Recruiting

  • Kaiser Permanente San Marcos Medical Offices

    San Marcos, California · Recruiting

  • Providence Saint Johns Health Center

    Santa Monica, California · Recruiting

  • Wellness Oncology and Hematology

    West Hills, California · Recruiting

  • Rocky Mountain Cancer Centers, Llp(Us Oncology Research)

    Lone Tree, Colorado · Recruiting

  • Danbury Hospital

    Danbury, Connecticut · Recruiting

  • Brcr Coral Springs

    Coral Springs, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • Cancer Care Centers of Brevard Palm Bay

    Palm Bay, Florida · Recruiting

  • Florida Clinical Trials Group Plantation

    Plantation, Florida · Recruiting

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida · Recruiting

  • The Oncology Institute of Hope and Innovation South Miami

    South Miami, Florida · Recruiting

  • Florida Clinical Trials Group Tamarac

    Tamarac, Florida · Recruiting

  • Moffitt Cancer Center McKinley Campus Richard M Shulze Family Foundation Outpatient Center

    Tampa, Florida · Recruiting

  • University Cancer and Blood Center Athens Comprehensive Cancer Center

    Athens, Georgia · Recruiting

  • Central Georgia Cancer Care Macon Office

    Macon, Georgia · Recruiting

  • Hawaii Cancer Care

    Honolulu, Hawaii · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Recruiting

  • Cancer Care Specialists For Illinois

    O'Fallon, Illinois · Recruiting

  • City of Hope Chicago Cancer Center

    Zion, Illinois · Recruiting

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana · Recruiting

  • Hematology Oncology of Indiana

    Indianapolis, Indiana · Recruiting

  • Mercy Medical Center

    Cedar Rapids, Iowa · Recruiting

  • Owensboro Health Mitchell Memorial Cancer Center

    Owensboro, Kentucky · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Aspirus St Lukes Hospital

    Duluth, Minnesota · Recruiting

  • Allina Health Cancer Institute Minneapolis

    Minneapolis, Minnesota · Recruiting

  • Metro Minnesota Community Oncology Research Consortium (Mmcorc)

    Saint Paul, Minnesota · Recruiting

  • Hattiesburg Hematology and Oncology Clinic

    Hattiesburg, Mississippi · Recruiting

  • Missouri Cancer Associates Columbia, Mo

    Columbia, Missouri · Recruiting

Showing 40 of 241 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.